President Trump’s executive order suspending federal funding for gain-of-function research not only contains questionable assertions, but it also frames the targeted research so broadly that it is likely to affect even lower-risk infectious disease research.
Related Posts
ASTP/ONC Rule Creates Prescription Drug Cost Transparency, Eases Administrative Burden, and Speeds Access to Care
ASTP/ONC released a final rule enabling the use of certified EHRs to submit prior authorizations, select drugs consistent with a patient’s insurance coverage, and exchange […]
A Massive Vaccine Experiment – The Atlantic
Two and a half years ago, Ashish Jha was the White House’s COVID-19 response coordinator, a job that meant getting as much of the country […]
Should health care spending make up 35% of GDP? – Healthcare Economist
Perhaps at least according to Tyler Cowen. Here is an excerpt from his Conversation with Dan Wang: WANG: …health care is […]